Android app Apple app link

Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook

By Yahoo! Finance   |   1 month ago
Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook

Beta Bionics Inc. (NASDAQ:BBNX) is a top stock pick with strong growth potential. Goldman Sachs upgraded the company with a $26 price target. Beta Bionics reported a 54% increase in net sales and raised its full-year guidance.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.